Rezumat: One of the most common gynecological pathologies is
the myoma, with a great socioeconomic burden. One
of the uterine-sparing treatment is represented by the
uterine artery embolization (UAE). The objective of
this study is to evaluate this treatment method mainly
through evolution of symptomatology and the quality
of life impact. We studied a number of 36 patients who
underwent UAE between January 2015 and March 2018.
They were evaluated at the beginning of the study, after
a month and after three months. At one month after the
procedure, we evaluated the evolution of symptomatology,
the Pictorial Blood Loss Assessment Chart (PBAC) score
and the ultrasound post-procedural aspects. In addition,
at three months we evaluated the quality of life impact
(uterine fibroid symptoms and health-related quality
of life questionnaire). At the final evaluation, 88.88%
of the patients reported a significant improvement in
symptomatology (z=-5.030; p<0.001), with a significant
reduction in PBAC score, the ultrasounds showed a decrease
in uterine fibroid volume (t=2.113; p=0.049) and the quality
of life was improved (p<0.001). UAE leads to the control of
fibroid-related symptoms and improves the quality of life. Cuvinte cheie: uterine artery embolization, quality of life,
minimally invasive treatment, PBAC, UFS-QoL.